[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1994

Cystic Fibrosis Carrier Screening in a High-Risk Population: Participation Based on a Traditional Recruitment Process

Author Affiliations

From the Division of Genetics (Dr Surh and Ms Mettler) and the Departments of Psychology (Dr Cappelli) and Pediatrics (Dr MacDonald), Children's Hospital of Eastern Ontario, Ottawa; and the Department of Internal Medicine, Ottawa General Hospital (Dr Dales).

Arch Pediatr Adolesc Med. 1994;148(6):632-637. doi:10.1001/archpedi.1994.02170060086017

Objective:  Recent advances in molecular genetic (DNA) technology have permitted identification of previously undetectable cystic fibrosis (CF) carriers. Although research has been initiated in the general population, to our knowledge no published studies have looked at the utilization of DNA-based carrier screening in the high-risk CF population (family history of CF).

Design:  Cross-sectional, diagnostic open trial.

Setting:  Carrier testing was offered to a high-risk CF population via adult patients with CF or parents of pediatric patients with CF attending two regional CF clinics over a 3-year period.

Participants:  Consecutive sample of virtually all patients with CF (n=118) from a population of 1 million.

Main Results:  Despite free services, written follow-up, and counseling for 99% of patients attending the CF clinic, there was less than 10% participation from high-risk family members (168 blood relatives and 26 spouses of identified carriers or patients with CF; 38 and 156 persons from the adult and pediatric clinic families, respectively). Nevertheless, we identified 91 CF carriers among the 168 high-risk relatives. This is comparable to the number of carriers detected in general population carrier screening that has tested substantially more individuals (>3000 per study).

Conclusions:  Our results suggest that research concerning CF carrier screening not only focus on data about fundamental program resources and numbers of carriers detected but also investigate how information about the availability of carrier screening is disseminated, the motivation behind testing, and the perceived relevance of test results by those tested in the high-risk population. These issues are increasingly relevant as screening becomes feasible using DNA testing for far more prevalent disorders (such as breast cancer and diabetes).(Arch Pediatr Adolesc Med. 1994;148:632-637)